Search is Powered by Google
Cancer / Oncology News

Greater Risk Of Cancers Associated With History Of Nonmelanoma Skin Cancer

Main Category: Cancer / Oncology
Also Included In: Dermatology
Article Date: 28 Aug 2008 - 3:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:1 star

1 (1 votes)

Article Opinions: 1 posts

Individuals with a history of nonmelanoma skin cancer (NMSC) are at increased risk for other cancers, according to a study published in the August 26 online issue of the Journal of the National Cancer Institute.

Previous studies have documented that people who have had nonmelanoma skin cancer were at increased risk for developing melanoma, but it is less well-established whether they were also at risk for cancers that do not involve the skin.

In the current study, Anthony Alberg, Ph.D., of the Medical University of South Carolina and colleagues analyzed data from a prospective cohort study called CLUE II, which was established in Washington County, Md., in 1989. Alberg's team compared the risk of malignancies in 769 individuals who had been diagnosed with nonmelanoma skin cancer and 18,405 individuals with no history of the disease during a 16-year follow-up period.

The overall incidence of cancers was 293.5 cases per 10,000 person-years in the participants with a history of nonmelanoma skin cancer and 77.8 per 10,000 in those individuals without a history of skin cancer. After adjusting for other known variables associated with cancer risk, including age, sex, body mass index, smoking status, and education level, the researchers found that individuals with a history of nonmelanoma skin cancer had a two-fold increase in the risk of subsequent cancers compared with individuals with no skin cancer history.

The increased risk remained statistically significant when the researchers removed melanoma from the list of subsequent cancers, indicating that the elevated risk was not restricted to melanoma. The association was observed for both types of nonmelanoma skin cancer, basal cell and squamous cell carcinoma.

The strongest association between a history of skin cancer and subsequent malignancies was seen in the youngest study participants, aged 25 to 44 years. "This pattern of associations, with earlier age of [nonmelanoma skin cancer] diagnosis being linked more strongly to the risk of developing subsequent malignancies, is consistent with the pattern that one would expect for a marker of inherited predisposition to cancer," the authors write.

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

Citation: Chen J, Ruczinski I, Jorgensen TJ, Yenokyan G, Yao Y, Alani R, Liégeois NJ, et al. Nonmelanoma Skin Cancer and Risk for Subsequent Malignancy. J Natl Cancer Inst 2008; 1215-1222

The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Visit the Journal online at http://jnci.oxfordjournals.org/.

Source: Liz Savage
htJournal of the National Cancer Institute




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Urology
ADHD Autism Diabetes

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
Shocking Pictures To Appear On Cigarette Packets In UK On 1st October
27 Sep 2008
The UK's ten million Smokers may see pictures of rotting teeth, throat cancer, and indications of male impotence (erectile dysfunction) on cigarette packets they buy at the beginning of October...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...